SUN PHARMACEUTICALS supplier risk profile Q1 2026: 107 shipments, 8 suppliers, India-dominant pharma imports.
SUN PHARMACEUTICALS imported 107 shipments in Q1 2026 across 8 suppliers and 4 countries. India dominates the sourcing footprint, accounting for 73% of all shipments, with SUN PHARMACEUTICAL (India) as the primary supplier at 68 shipments. The company sources exclusively within HS Chapter 30 (Pharmaceutical Products), reflecting a concentrated, vertically-integrated supply chain. Netherlands and Israel account for smaller volumes at 8% and 3% respectively.
Distance-screened against all 380 facilities in the ASPI Xinjiang Data Project. Proximity score: 100 / 100.
Three names matching SUN PHARMACEUTICALS appear on sanctions watchlists during the review period. The importer shows no identified suppliers with documented Uyghur Forced Labor Prevention Act (UFLPA) exposure.
8 distinct tier-1 suppliers in Q1 2026
| SUN PHARMACEUTICAL | India | 68 |
| SUN PHARMACEUTICAL | Netherlands | 9 |
| SUN PHARMACEUTICAL LIMI | India | 4 |
| TARO PHARMACEUTICAL | Israel | 3 |
| GLAND PHARMA | India | 3 |
| SUN PHARMACEUTICAL LIMIT | India | 2 |
| COHANCE LIFESCIENCES | India | 1 |
| ALKALOIDA CHEMICAL ZRT | Germany | 1 |
Share of Q1 2026 inbound shipments by source country
1 tier-2 + 11 tier-3 nodes mapped - sign up to see them.
Free Tarifflo account unlocks the complete tier 1 / 2 / 3 supplier graph, daily refresh, alerts, and sanctions + UFLPA monitoring on every shipment.